Barorezeptoraktivierungstherapie bei therapierefraktärer Hypertonie: Indikation und Patientenselektion: Empfehlungen der BAT-Konsensusgruppe 2017

H-G Predel; M Koziolek; J Beige; M Wallbach; D Zenker; G Henning; M Halbach; N Mader; F Mahfoud; G Schlieper; V Schwenger; M Hausberg; J Börgel; M Lodde; M van der Giet; J Müller-Ehmsen; J Passauer; S Parmentier; S Lüders; B K Krämer; S Büttner; F Limbourg; J Jordan; O Vonend; H Reuter

doi:10.1007/s00108-017-0308-y

Barorezeptoraktivierungstherapie bei therapierefraktärer Hypertonie: Indikation und Patientenselektion: Empfehlungen der BAT-Konsensusgruppe 2017

H-G Predel, M Koziolek, J Beige, M Wallbach, D Zenker, G Henning, M Halbach, N Mader, F Mahfoud, G Schlieper, V Schwenger, M Hausberg, J Börgel, M Lodde, M van der Giet, J Müller-Ehmsen, J Passauer, S Parmentier, S Lüders, B K KrämerS Büttner, F Limbourg, J Jordan, O Vonend, H Reuter

Abteilung Präventive und rehabilitative Sport- und Leistungsmedizin

Publikation: Beitrag in Fachzeitschrift › Zeitschriftenaufsätze › Forschung › Begutachtung

Abstract

Baroreceptor activation therapy (BAT) has been available for several years for treatment of therapy-refractory hypertension (trHTN). This procedure is currently being carried out in a limited number of centers in Germany, also with the aim of offering a high level of expertise through sufficient experience; however, a growing number of patients who are treated with BAT experience problems that treating physicians are confronted with in routine medical practice. In order to address these problems, a consensus conference was held with experts in the field of trHTN in November 2016, which summarizes the current evidence and experience as well as the problem areas in handling BAT patients.

Titel in Übersetzung	Baroreceptor activation therapy for therapy-resistant hypertension: indications and patient selection : Recommendations of the BAT consensus group 2017
Originalsprache	Deutsch
Zeitschrift	Der Internist
Jahrgang	58
Ausgabenummer	10
Seiten (von - bis)	1114-1123
Seitenumfang	10
ISSN	0020-9554
DOIs	https://doi.org/10.1007/s00108-017-0308-y
Publikationsstatus	Veröffentlicht - 10.2017

Zugriff auf Dokument

10.1007/s00108-017-0308-y

Zitation

Predel, H-G., Koziolek, M., Beige, J., Wallbach, M., Zenker, D., Henning, G., Halbach, M., Mader, N., Mahfoud, F., Schlieper, G., Schwenger, V., Hausberg, M., Börgel, J., Lodde, M., van der Giet, M., Müller-Ehmsen, J., Passauer, J., Parmentier, S., Lüders, S., ... Reuter, H. (2017). Barorezeptoraktivierungstherapie bei therapierefraktärer Hypertonie: Indikation und Patientenselektion: Empfehlungen der BAT-Konsensusgruppe 2017. Der Internist, 58(10), 1114-1123. https://doi.org/10.1007/s00108-017-0308-y

@article{f36ae5d37dc84ce585c41af80d6ac8a8,

title = "Barorezeptoraktivierungstherapie bei therapierefrakt{\"a}rer Hypertonie: Indikation und Patientenselektion: Empfehlungen der BAT-Konsensusgruppe 2017",

abstract = "Baroreceptor activation therapy (BAT) has been available for several years for treatment of therapy-refractory hypertension (trHTN). This procedure is currently being carried out in a limited number of centers in Germany, also with the aim of offering a high level of expertise through sufficient experience; however, a growing number of patients who are treated with BAT experience problems that treating physicians are confronted with in routine medical practice. In order to address these problems, a consensus conference was held with experts in the field of trHTN in November 2016, which summarizes the current evidence and experience as well as the problem areas in handling BAT patients.",

keywords = "English Abstract, Journal Article, Review",

author = "H-G Predel and M Koziolek and J Beige and M Wallbach and D Zenker and G Henning and M Halbach and N Mader and F Mahfoud and G Schlieper and V Schwenger and M Hausberg and J B{\"o}rgel and M Lodde and {van der Giet}, M and J M{\"u}ller-Ehmsen and J Passauer and S Parmentier and S L{\"u}ders and Kr{\"a}mer, {B K} and S B{\"u}ttner and F Limbourg and J Jordan and O Vonend and H Reuter",

year = "2017",

month = oct,

doi = "10.1007/s00108-017-0308-y",

language = "Deutsch",

volume = "58",

pages = "1114--1123",

journal = "Der Internist",

issn = "0020-9554",

publisher = "Springer Verlag",

number = "10",

}

Predel, H-G, Koziolek, M, Beige, J, Wallbach, M, Zenker, D, Henning, G, Halbach, M, Mader, N, Mahfoud, F, Schlieper, G, Schwenger, V, Hausberg, M, Börgel, J, Lodde, M, van der Giet, M, Müller-Ehmsen, J, Passauer, J, Parmentier, S, Lüders, S, Krämer, BK, Büttner, S, Limbourg, F, Jordan, J, Vonend, O & Reuter, H 2017, 'Barorezeptoraktivierungstherapie bei therapierefraktärer Hypertonie: Indikation und Patientenselektion: Empfehlungen der BAT-Konsensusgruppe 2017', Der Internist, Jg. 58, Nr. 10, S. 1114-1123. https://doi.org/10.1007/s00108-017-0308-y

TY - JOUR

T1 - Barorezeptoraktivierungstherapie bei therapierefraktärer Hypertonie

T2 - Indikation und Patientenselektion: Empfehlungen der BAT-Konsensusgruppe 2017

AU - Predel, H-G

AU - Koziolek, M

AU - Beige, J

AU - Wallbach, M

AU - Zenker, D

AU - Henning, G

AU - Halbach, M

AU - Mader, N

AU - Mahfoud, F

AU - Schlieper, G

AU - Schwenger, V

AU - Hausberg, M

AU - Börgel, J

AU - Lodde, M

AU - van der Giet, M

AU - Müller-Ehmsen, J

AU - Passauer, J

AU - Parmentier, S

AU - Lüders, S

AU - Krämer, B K

AU - Büttner, S

AU - Limbourg, F

AU - Jordan, J

AU - Vonend, O

AU - Reuter, H

PY - 2017/10

Y1 - 2017/10

N2 - Baroreceptor activation therapy (BAT) has been available for several years for treatment of therapy-refractory hypertension (trHTN). This procedure is currently being carried out in a limited number of centers in Germany, also with the aim of offering a high level of expertise through sufficient experience; however, a growing number of patients who are treated with BAT experience problems that treating physicians are confronted with in routine medical practice. In order to address these problems, a consensus conference was held with experts in the field of trHTN in November 2016, which summarizes the current evidence and experience as well as the problem areas in handling BAT patients.

AB - Baroreceptor activation therapy (BAT) has been available for several years for treatment of therapy-refractory hypertension (trHTN). This procedure is currently being carried out in a limited number of centers in Germany, also with the aim of offering a high level of expertise through sufficient experience; however, a growing number of patients who are treated with BAT experience problems that treating physicians are confronted with in routine medical practice. In order to address these problems, a consensus conference was held with experts in the field of trHTN in November 2016, which summarizes the current evidence and experience as well as the problem areas in handling BAT patients.

KW - English Abstract

KW - Journal Article

KW - Review

U2 - 10.1007/s00108-017-0308-y

DO - 10.1007/s00108-017-0308-y

M3 - Zeitschriftenaufsätze

C2 - 28835975

SN - 0020-9554

VL - 58

SP - 1114

EP - 1123

JO - Der Internist

JF - Der Internist

IS - 10

ER -

Barorezeptoraktivierungstherapie bei therapierefraktärer Hypertonie: Indikation und Patientenselektion: Empfehlungen der BAT-Konsensusgruppe 2017

Abstract

Zugriff auf Dokument

Fingerprint

Zitation